• 1. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 4. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 5. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Nitrobenzenes Nitrophenyl ethers

Professional Introduction to 4-(Difluoromethyl)-2-nitroaniline (CAS No. 887412-09-1)

4-(Difluoromethyl)-2-nitroaniline, identified by its Chemical Abstracts Service (CAS) number 887412-09-1, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, characterized by its nitro and difluoromethyl substituents, exhibits unique chemical properties that make it a valuable intermediate in the synthesis of various biologically active molecules.

The structural framework of 4-(Difluoromethyl)-2-nitroaniline consists of an aniline core, which is a well-known aromatic amine, modified by the presence of a nitro group at the 2-position and a difluoromethyl group at the 4-position. This specific arrangement imparts distinct reactivity and electronic characteristics, making it a versatile building block for further chemical modifications. The nitro group, in particular, is known for its ability to participate in nucleophilic aromatic substitution reactions, while the difluoromethyl group can enhance metabolic stability and binding affinity in drug candidates.

In recent years, there has been a growing interest in exploring the pharmacological potential of compounds containing both nitro and difluoromethyl groups. These functional moieties are frequently incorporated into drug molecules due to their ability to modulate biological pathways and improve pharmacokinetic profiles. For instance, studies have demonstrated that nitroaromatic compounds can exhibit potent antimicrobial and anti-inflammatory properties, while difluoromethyl groups are often used to enhance lipophilicity and reduce susceptibility to metabolic degradation.

One of the most compelling aspects of 4-(Difluoromethyl)-2-nitroaniline is its utility as a precursor in the synthesis of novel therapeutic agents. Researchers have leveraged its reactivity to develop compounds with potential applications in oncology, neurology, and infectious diseases. For example, derivatives of this compound have been investigated for their ability to inhibit specific enzymes or receptors involved in disease pathogenesis. The presence of both the nitro and difluoromethyl groups allows for fine-tuning of the molecule's properties, enabling the optimization of potency, selectivity, and pharmacokinetic behavior.

The synthesis of 4-(Difluoromethyl)-2-nitroaniline typically involves multi-step organic transformations that require careful control over reaction conditions. Common synthetic routes include nitration of aniline derivatives followed by selective fluorination. Advanced techniques such as palladium-catalyzed cross-coupling reactions have also been employed to introduce the difluoromethyl group with high efficiency. These synthetic strategies highlight the compound's importance as a synthetic intermediate and underscore the expertise required to produce it in high purity.

From a computational chemistry perspective, the molecular structure of 4-(Difluoromethyl)-2-nitroaniline has been extensively studied using various modeling techniques. Quantum mechanical calculations have provided insights into its electronic structure and reactivity patterns, aiding in the design of more effective synthetic routes. Additionally, molecular docking studies have been performed to evaluate its potential binding interactions with biological targets. These computational approaches are crucial for understanding how this compound behaves within biological systems and for guiding the development of novel drug candidates.

The pharmacological evaluation of 4-(Difluoromethyl)-2-nitroaniline has revealed several promising avenues for therapeutic intervention. In vitro assays have demonstrated its ability to interact with specific proteins and enzymes relevant to various diseases. For instance, preliminary studies suggest that it may inhibit kinases involved in cancer cell proliferation or modulate neurotransmitter receptors in neurological disorders. While these findings are encouraging, further research is necessary to fully elucidate its mechanism of action and therapeutic potential.

The safety profile of 4-(Difluoromethyl)-2-nitroaniline is another critical consideration in its development as a pharmaceutical intermediate. Toxicological studies have been conducted to assess its acute and chronic effects on living systems. These investigations have provided valuable data on its metabolic pathways and potential side effects, which are essential for ensuring its safe use in drug development. By adhering to stringent regulatory guidelines, researchers can mitigate risks associated with handling this compound.

The future prospects for 4-(Difluoromethyl)-2-nitroaniline are bright, particularly as advancements in synthetic chemistry and drug discovery continue to evolve. Its unique structural features make it an attractive candidate for further exploration in medicinal chemistry. Collaborative efforts between academia and industry are likely to drive innovation in this area, leading to the development of new drugs that address unmet medical needs.

• 2267-23-4(2-Nitro-4-(trifluoromethoxy)aniline)
• 713-65-5(1-Nitro-4-(trifluoromethoxy)benzene)
• 2995-45-1(1-Nitro-3-(trifluoromethoxy)benzene)
• 235101-48-1(2-Nitro-6-(trifluoromethoxy)aniline)
• 22236-07-3(3-(Difluoromethoxy)nitrobenzene)
• 105552-71-4(Benzene, 1-(difluoromethoxy)-2,3-dimethoxy-5-nitro-)
• 1215206-37-3(N-Methyl-2-nitro-4-(trifluoromethoxy)aniline)
• 1544-86-1(4-(Difluoromethoxy)nitrobenzene)
• 1019997-75-1(1-nitro-3-(4-(trifluoromethoxy)phenoxy)benzene)
• 700804-01-9(Phenol, 2-(difluoromethoxy)-5-nitro-)